CNBG’s mRNA vaccine industrial base breaks ground in Shanghai
Published: Sep 25, 2021 10:28 PM
CNBG mRNA vaccine Photo:VCG


An mRNA vaccine industrial base under the China National Biotec Group (CNBG) broke ground in Shanghai on Saturday, a milestone for the leading Chinese vaccine producer to push forward its vaccine production amid the coronavirus pandemic. 

The vaccine base of the Virogin-CNBG Joint Venture covers 32,500 square meters, with the production workshop accounting for half the area, according to an announcement by CNBG on Saturday. Virogin Biotech is a Vancouver-based developer of next-generation oncolytic virus therapeutics. 

Once completed, the smart and environmental friendly industrial base will become a leading mRNA vaccine producer in terms of designed capacity and technology. 

Local government officials in Shanghai said they will give strong support to the company as the bioengineering and pharmaceutical industry is a pillar industry of the city.